Oxolamine
- R05DB07 (WHO)
- N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine
- 959-14-8 Y
- 13738
- DB13216 Y
- 13143 Y
- 90BEA145GY
- D07387 Y
- ChEMBL1620875 N
- DTXSID5023403
- Interactive image
- n1c(onc1c2ccccc2)CCN(CC)CC
- InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3 Y
- Key:IDCHQQSVJAAUQQ-UHFFFAOYSA-N Y
Oxolamine is a cough suppressant[1] that is available as a generic drug in many jurisdictions.[2]
Oxolamine also has anti-inflammatory activity, which causes a reduction in irritation of the nerve receptors of the respiratory tract.[3]
It is mainly used for the treatment of pharyngitis, tracheitis, bronchitis, bronchiectasis and pertussis.[3]
Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant. It is listed as a prescription drug in New Zealand legislation. Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflammation.[4]
References
- ^ de Groot AC (2022). "3.357 Oxolamine". Systemic Drugs. Monographs in Contact Allergy. Vol. 4 (First ed.). CRC Press. p. 712. ISBN 978-1-00-054991-1.
- ^ "Oxolamine". drugs.com. 19 April 2015. Archived from the original on 20 September 2018. Retrieved 23 January 2018.
- ^ a b "NCATS Inxight Drugs — OXOLAMINE CITRATE". drugs.ncats.io. Archived from the original on 2022-09-26. Retrieved 2022-09-26.
- ^ "Oxolamine". go.drugbank.com. Archived from the original on 2022-09-26. Retrieved 2022-09-26.
- v
- t
- e
- Acetylcysteine#
- Ambroxol
- Bromhexine
- Carbocisteine
- Dembrexine hydrochloride
- Domiodol
- Dornase alfa
- Eprazinone
- Erdosteine
- Letosteine
- Mannitol
- Mesna
- Neltenexine
- Sobrerol
- Stepronin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e